ImmunityBio (IBRX) Interest Expenses (2016 - 2026)

ImmunityBio (IBRX) has 10 years of Interest Expenses data on file, last reported at $14.6 million in Q1 2026.

• Interest Expenses for Q1 2026 came in at $14.6 million, down 4.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.2 million (down 40.1% YoY), and the FY2025 annual result was $60.9 million, down 46.87% from the prior year.
• Interest Expenses slipped to $14.6 million in Q1 2026 per IBRX's latest filing, from $14.8 million in the prior quarter.
• Over five years, Interest Expenses peaked at $35.0 million in Q3 2023 and troughed at -$18.7 million in Q4 2022.
• A 5-year average of $17.9 million and a median of $15.5 million in 2025 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2022 and 2024: Interest Expenses plunged 515.43% in 2022, then soared 6405.25% in 2024.
• A 5-year view of Interest Expenses shows it stood at -$18.7 million in 2022, then surged by 102.14% to $400000.0 in 2023, then soared by 6405.25% to $26.0 million in 2024, then sank by 42.96% to $14.8 million in 2025, then declined by 1.68% to $14.6 million in 2026.
• Business Quant data shows IBRX's Interest Expenses at $14.6 million in Q1 2026, $14.8 million in Q4 2025, and $15.3 million in Q3 2025.